Suven Pharmaceuticals Limited has become a wholly owned subsidiary of Suven Life Sciences Limited focused on contract development and manufacturing operations (CDMO) and CRAMS specialty chemicals and formulation business. It has four commercial molecules under CDMO that are under patent protection until 2025. Suven is among the top two suppliers of intermediates for these molecules. The company has healthy financials with annual sales growth over 20%, profit growth over 14%, and stock price CAGR over 69%. It has low debt and high returns on equity and capital employed. The company is expected to continue growing its revenue by 10-15% annually through commercializing new facilities.